Alx Oncology Holdings (ALXO) Short term Debt (2020 - 2026)

Alx Oncology Holdings' Short term Debt history runs 7 years deep, the most recent figure standing at $5.2 million for Q1 2026.

• In Q1 2026, Short term Debt rose 200.0% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $5.2 million (up 200.0% YoY), while the FY2025 annual figure was $5.2 million, up 1099.31% from the prior year.
• Short term Debt came in at $5.2 million for Q1 2026 at Alx Oncology Holdings, roughly flat from $5.2 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $5.2 million in Q4 2025 to a low of $435000.0 in Q4 2024.
• A 5-year average of $2.8 million and a median of $2.6 million in 2022 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt advanced 1.23% in 2022 and surged 1099.31% in 2025, its largest moves.
• Alx Oncology Holdings' Short term Debt stood at $1.6 million in 2022, then slumped by 49.7% to $830000.0 in 2023, then slumped by 47.59% to $435000.0 in 2024, then soared by 1099.31% to $5.2 million in 2025, then changed by 0.0% to $5.2 million in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $5.2 million, $5.2 million, and $4.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison